Variation of growth in the production of the BCG vaccine and the association with the immune response. An observational study within a randomised trial. Issue 17 (21st April 2015)

• Record Type: Journal Article
• Authors: Biering-Sørensen, Sofie; Jensen, Kristoffer Jarlov; Aamand, Susanne Havn; Blok, Bastiaan; Andersen, Andreas; Monteiro, Ivan; Netea, Mihai G.; Aaby, Peter; Benn, Christine Stabell; Hasløv, Kaare Robert
• Is Part Of: Vaccine. Volume 33:Issue 17(2015)
• Page Start: 2056
• Page End: 2065
• Publication Date: 2015-04-21
• Subjects: BCG Bacille Calmette–Guérin -- BHP Bandim Health Project -- CI confidence interval -- GMR geometric mean ratio -- HDSS Health and Demographic Surveillance System -- LBW low-birth-weight -- NSE non-specific effects -- PBMCs peripheral blood mononuclear cells -- PPD purified protein derivative (from Mycobacterium tuberculosis) -- PR prevalence ratio -- RCT randomised-controlled trial -- S1 growth of the BCG culture in the first passage -- SSI Statens Serum Institut; Bacillus Calmette–Guérin -- Immunogenicity -- Tuberculin PPD -- Cytokine -- Infant -- Vaccine production -- Heterologous immunity; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.02.056
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: The production of live BCG vaccine is subject to variation in bacterial growth rate. Slow growing BCG was associated with higher frequency of scars and PPD responses. Slow growing BCG was associated with higher cytokine responses in monocytes. Subtle changes in the production of BCG vaccine may influence its immunogenicity. Abstract: Introduction: Bacille Calmette–Guérin (BCG) vaccine has beneficial non-specific effects on overall survival. After BCG vaccination, positive PPD response and scar formation are associated with increased survival. During a trial randomising low-birth-weight neonates to BCG at birth or the usual delayed BCG, the manufacturer of the BCG vaccine experienced a period with relatively slow growth rate of the BCG. We investigated the association between growth rate of BCG when manufacturing the vaccine and its capability to induce immune responses in vivo and in vitro . Methods: 1633 neonates were randomised to BCG at birth and examined for scar at 12 months; a subgroup was tested for PPD response at 2 and 6 months. The BCG batches from the Slow growth period were compared with the precedent and subsequent Normal growth batches with regard to prevalence and size of BCG scar and PPD response. We also tested the effect of batches on in vitro cytokine responses. Results: At 12 months, the Slow growth batches were associated with higher BCG scar prevalence (98.2%) than the precedent batches (92.3%, p = 0.01) but the prevalence remained high after return to normal growth (98.8%, p = 0.52). The Slow growth batches were associated with larger scar size (5.0 mm) than precedent (4.4 mm, p < 0.01) and subsequent batches (4.8 mm, p = 0.03). Compared with Normal growth batches, the Slow growth batches were associated with a higher prevalence of positive PPD responses, and among PPD positive children, a larger PPD reaction (geometric mean ratio: 1.40 (1.20–1.63)) at 2 months. In response to secondary heterologous stimulation, monocytes primed with Slow growth batches induced higher IL-6 ( p = 0.03) and TNF-α responses ( p = 0.03) compared with Normal growth batches. Conclusion: The study indicates that variations in the production of BCG vaccine may influence important immunological effects of the vaccine. Trial registration: clinicaltrials.gov (NCT00625482 ).